News >

Myeloma Expert Stresses Significance of Appropriate Diagnostic Work-up

Gina Columbus @ginacolumbusonc
Published: Friday, Jul 28, 2017

Dr Reed Friend
Reed Friend, MD
Appropriately diagnosing a patient with multiple myeloma is a key point in their potential treatment, which has been further characterized by the revision of the International Myeloma Working Group criteria for the diagnosis of myeloma.

The diagnostic criteria, which was updated in 2014, addresses other clinical features aside from the CRAB criteria—defined as increased calcium level, renal dysfunction, anemia, and destructive bone lesions—for patients to be considered for treatment. These also include biomarkers of 60% or greater clonal plasma cells on bone marrow examination and a serum involved/uninvolved free light chain ratio of 100 or greater.

“Sometimes, we see patients with these factors that [show that] maybe [they] should be treated a little bit earlier,” said Reed Friend, MD.

Friend, a medical oncologist in hematology and medical oncology, of Levine Cancer Institute and Carolinas HealthCare System, discussed the revised steps in diagnosing patients with multiple myeloma and prognostic factors, as well as existing challenges and hopes for the field’s future in an interview during the 2017 OncLive® State of the Science SummitTM on Multiple Myeloma.  

OncLive: You spoke on diagnosis and prognosis of multiple myeloma. What were the highlights of your presentation?

Friend: In terms of the diagnosis and prognosis of multiple myeloma, the biggest thing is making sure that local providers and physicians who see patients with suspected myeloma are appropriately working them up. A lot of patients can be missed in terms of diagnosis if you are not ordering the right tests. In terms of work-up, the most common things people forget to order are the serum-free light chains and the urine studies. With imaging surveys, some people miss [myeloma].

Even on a skeletal survey, you can only detect up to 50% to 70% of the bone damage that occurs. You have these early damage things that occur on the bone, in the marrow, from myeloma. That is not being detected on the skeletal surveys. If you are suspecting damage in the bones, then you would want to further work it up with the whole-body MRI, where you can get a more sensitive approach to the marrow damage. 

Also, plasmacytomas can occur. You would really only be able to see that on something like a PET/CT scan, where you see the hypermetabolic activity happening. 

What advice can you provide to community oncologists on ensuring they are getting the appropriate work-up for their patients?

It might be more of getting the right tests done, being as comprehensive as possible, and not missing things. Another thing that is important, and has recently been updated as of 2014, is the diagnostic criteria has been revised to include bone marrow involvement of plasma cells greater than 60%. Even if you don’t meet those classic CRAB criteria—the hypercalcemia, the renal dysfunction, anemia, the bone lytic lesions—if you have someone who has bone marrow with greater than 60% plasma cells, they need to be treated.

Another thing that came out with the revised criteria is, if you have greater than 100 serum free light chain over the involved/uninvolved ratio—so, that is important to take into consideration. If you find more than 1 lesion on the MRI, the PET/CT scan, then the patient needs to be treated or considered for treatment.

What are your thoughts on a multidisciplinary approach for patients with multiple myeloma?

I have always been about the multidisciplinary approach. I saw a couple of patients [recently]; 1 of them has other comorbidities aside from their newly diagnosed multiple myeloma. And, they’re asking about diets. We have a dietician in our clinic who meets with our patients and helps them configure what kind of diet would be best for them.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication